The inclusion of SARS-CoV-2 in the BIOFIRE® RP2.1 panel allows healthcare providers to quickly identify patients with common respiratory pathogens, as well as those with COVID-19, using one ...

The BIOFIRE Respiratory Panel 2.1 plus (RP2.1 plus) tests for 23 pathogens (19 viruses, including SARS-CoV-2, and 4 bacteria) responsible for the most frequent respiratory tract infections.

The BD MAX Respiratory Viral Panel detected and differentiated between influenza A and B respiratory syncytial virus and SARS-CoV-2. The panel requires less than 1.5 minutes hands-on time per sample.

NEWARK, DE / ACCESS Newswire/ February 18, 2025 / The global swab and viral transport medium marketis projected to witness consistent growth over the next decade, reaching approximately USD 9,714. ...

With the addition of the SARS-CoV-2 virus, the panel now includes 19 viral and 2 bacterial targets.

Rather than running multiple tests on samples, the PKamp Respiratory SARS-CoV-2 RT-PCR Panel is designed to conserve resources by testing a single nasopharyngeal, oropharyngeal or nasal swab sample ...

The US Food and Drug Administration (FDA) granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification ...

The new BD MAX Respiratory Viral Panel can test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) at once.

Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper a ...

QIAGEN (QGEN) receives FDA clearance for the QIAstat-Dx respiratory syndromic testing panel for fast and accurate results.